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Background: Haemoglobin A1c (HbA1c) is defined by the International Federation of Clinical Chemistry 
(IFCC) working group as haemoglobin that is irreversibly glycated at one or both N-terminal valines of the 
beta chains. Various factors may affect the accuracy of HbA1c measurements according to the assay 
method used and haemoglobin variants represent one of them. Hb C is caused by the substitution of 
glutamic acid for lysine at position 6 of the ß-globin chain and is commonly found in West Africa and the 
Caribbean regions. Hb D is caused by the substitution of glutamine for glutamic acid at position 121 of the 
ß-globin chain. It is usually found in the Sikhs of the Punjab region of the Indian subcontinent. 
 
Objective: To report a case of a diabetic patient with clinically silent haemoglobin variant, causing 
undetectable HbA1c concentration measured by high performance liquid chromatography (HPLC) method. 
 
Case Summary: Our patient was a Caucasian 64-year-old female with type 2 diabetes mellitus for 5 years 
treated by diet, sulfonylureas and metformin. She had a history of breast cancer treated by surgery and 
curietherapy. Her mother had a type 2 diabetes. The patient lived in Germany before coming for the first 
time in our unit. During the hospitalization for check up, determination of HbA1c level were performed. 
HbA1c concentrations measured using a HPLC method (Adams ARKRAY, KYOTO, Japan distributed 
through Menarini, Italy) were undetectable. An electrophoresis of hemoglobin reported: HbA 0% (normal 
range 94,5-98,5), HbA2 2,4% (1,5-3,5), HbC 43,1% (0%), HbD 53,8% (0%). A research of ß-thalassemia 
with study of ß-Globin HBB gene was performed using Polymerase Chain Reaction amplification and 
promoter sequencing of HBB gene methods. The results confirmed an haemoglobin variant C/D with 2 
mutations (p.E6K and p.E122Q). 
 
Conclusions: Clinical laboratories should be aware of limitations of the HbA1cassay method used, such 
as a potential interference with haemoglobin variant as illustrated by our case. Alternative methods for 
monitoring glycaemic control in these patients should be considered as, for instance, dosage of 
fructosamine or use of continuous glucose monitoring system. 
 
 
